The tumor microenvironment (TME) commonly displays an upregulation of immune checkpoint ligands, such as PD‐L1,77 and a downregulation of stimulatory molecules such as MHC I.78The expression of immune checkpoints can dampen anticancer immune responses, and immune checkpoint expression on CD8+ T cells has been associated with poor clinical outcome.79, 80, 81. Here, CD274 is linked to neoplasm.